Table 3.
Main results from phase 3 trials with ALK inhibitors in the front-line setting.
| Drug | Trial Name | Control Arm | Primary Endpoint | BIRC-mPFS (Months) |
|---|---|---|---|---|
| Crizotinib | PROFILE-1014 [9,10] | Pemetrexed-based chemotherapy | BIRC-mPFS | 10.9 |
| Ceritinib | ASCEND-4 [11,12] | Pemetrexed-based chemotherapy | BIRC-mPFS | 16.6 |
| Alectinib | ALEX [13] | Crizotinib | mPFS | 25.7 |
| Brigatinib | ALTA-1L [14] | Crizotinib | BIRC-mPFS | 24.0 |
| Ensartinib | EXALT-3 [17] | Crizotinib | BIRC-mPFS | 25.8 |
| Lorlatinib | CROWN [18,19,20] | Crizotinib | BIRC-mPFS | NR |
BIRC: blinded independent radiologic review, mPFS: median progression-free survival, NR: not reached.